Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$10.78 USD

10.78
356,061

+0.08 (0.75%)

Updated May 15, 2024 04:00 PM ET

After-Market: $10.74 -0.04 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why Is Agenus (AGEN) Down 17.7% Since its Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss

    Agenus (AGEN) posts wider-than-expected loss and misses on revenue estimate in the fourth quarter of 2017.

      Agenus (AGEN) Reports Wider than Expected Q4 Loss, Sales Miss

      Agenus reports wider than expected loss and misses sales estimates in the fourth quarter of 2017.

        What's in Store for Agenus (AGEN) This Earnings Season?

        Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.

          Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?

          Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

            Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why

            Spectrum Pharmaceuticals (SPPI) stock is witnessing significant momentum mainly on encouraging data from poziotinib study.

              BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

              BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

                Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%

                Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares more than 11% on the day amid huge volumes.

                  Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

                  Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.

                    Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

                    Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.

                      Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

                      Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

                        Agenus (AGEN) Reports In Line Q3 Loss, Sales Miss Estimates

                        Agenus reported in line loss in the third quarter of 2017 but sales missed expectations.

                          Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

                          Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.

                            What's in Store for Ligand (LGND) This Earnings Season?

                            Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.

                              What's in Store for Madrigal (MDGL) This Earnings Season?

                              Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.

                                Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?

                                Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.

                                  What's in Store for Catalyst (CPRX) This Earnings Season?

                                  Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

                                    What's in the Cards for Merrimack (MACK) in Q3 Earnings?

                                    Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                                      What's in the Cards for Repros (RPRX) This Earnings Season?

                                      Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                                        Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates

                                        Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.

                                          Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

                                          Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

                                            Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

                                            Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                                              Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?

                                              Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.

                                                AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook

                                                AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.

                                                  Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)

                                                  Horizon Pharma???s shares have declined 12% in the year so far, underperforming the industry???s gain of 0.9%.